BridgeBio Oncology Touts Best in RAS Pipeline, Highlights BBO-8520 Response and Combo Tolerability
Executives from BridgeBio Oncology Therapeutics (NASDAQ:BBOT) outlined the company's strategy to build what they call the Best in RAS pipeline during an Oppenheimer-hosted discussion, emphasizing...